Stay updated on Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check20 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check63 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed information about a phase II trial involving pembrolizumab for glioblastoma, while adding new identifiers and procedural details related to glioblastoma treatment, including radiation therapy and the drug temozolomide.SummaryDifference46%
- Check70 days agoChange DetectedThe page has been updated to reflect a new phase II study of Pembrolizumab in treating glioblastoma, with revised dates and definitions for key study metrics, including overall survival and disease progression assessments.SummaryDifference10%
- Check78 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page.